1月9日，苏州瑞博生物技术股份有限公司（以下简称：瑞博生物；股票代码：06938.HK）正式于香港 联合交易所挂牌上市。在近年来港股生物科技板块持续深化发展、监管环境不断优化的背景下，具备扎 实技术与清晰管线的创新药企愈发受到投资者关注，瑞博生物的上市为此再添例证。 瑞博生物此次全球发售共计3161.04万股，发行价为每股57.97港元，首日开盘报75港元，较发行价上涨 29.38%。本次招股公开发售部分获超100倍认购，国际发售部分达到16.7倍认购，募集资金总额超18亿 港元。 作为中国小核酸技术与制药领域的主要开拓者，瑞博生物此次上市吸引了多家国内外知名投资机构的参 与，包括华夏基金、大成基金、大成国际及泰康人寿等国内头部投资机构，以及Arc Avenue， Himension Fund、Erik Selin Fastigheter AB等国际资本，体现了全球投资者对小核酸赛道价值及公司实 力的高度认可。 行业前景广阔，管线瞄准巨大未满足临床需求 瑞博生物所专注的领域，正对应着广阔的市场前景与迫切的未满足临床需求。全球小核酸药物市场正处 于高速增长通道，根据弗若斯特沙利文报告，全球小核酸药物市场已从20 ...

Investment Rating - The report maintains a recommendation for the small nucleic acid industry, indicating a positive outlook for investment opportunities in this sector [3]. Core Insights - The small nucleic acid industry is entering a critical phase for forward-looking investments, with domestic companies showing significant advantages. The report emphasizes the importance of technological breakthroughs and the evolving landscape of the industry [1][7]. - The report highlights that 2026 is expected to be a catalytic year for the small nucleic acid industry, with an increase in investable companies and significant advancements in technology [14]. Summary by Sections 1. Investment Opportunities in Small Nucleic Acids - The pharmaceutical investment landscape is closely tied to industry trends, with the small nucleic acid sector entering a multi-dimensional breakthrough era. Historical trends in innovative drug markets indicate that major market movements are driven by technological advancements and subsequent domestic adaptations [11][14]. - The report outlines that the small nucleic acid industry is transitioning towards breakthroughs by domestic companies and is poised for global competition [7][14]. 2. Competitive Advantages of Chinese Companies - The key to small nucleic acid drug development lies in the combination of effective delivery platforms and target identification. Chinese companies are noted for their efficiency in research and development, particularly in the context of established delivery systems [17][28]. - The report discusses the importance of speed and innovation in drug development, emphasizing that Chinese firms excel in these areas, which enhances their competitive edge in the small nucleic acid market [23][28]. 3. Investment Timing and Global Company Analysis - Alnylam is identified as a leading player in the small nucleic acid field, with expectations of profitability by 2025. The company has successfully commercialized several products, leveraging its GalNAc delivery system to establish a strong market position [40][43]. - Arrowhead is also highlighted for its innovative delivery systems and diverse target strategies, aiming to achieve breakthroughs in new therapeutic areas [46][48]. 4. Relevant Investment Targets - Several companies are identified as potential investment opportunities within the small nucleic acid sector: - **Bohua Pharmaceutical**: Noted for its advanced cardiovascular projects and collaboration with Novartis, which enhances its credibility and market position [62]. - **Rebio Biotech**: Recognized for its rapid clinical development of FXI factor anticoagulant drugs, indicating a strong pipeline in treating thrombotic diseases [7]. - **Sengin Biotech**: Focused on developing siRNA drugs for obesity and cardiovascular metabolic diseases, showcasing a commitment to innovative therapeutic solutions [7]. - **Frontier Biotech**: Reported to have promising preclinical data for its complement protein-targeting small nucleic acids [7]. - **Dongyang Sunshine Pharmaceutical**: Established a comprehensive research platform for small nucleic acids, originating from hepatitis B research [7].

Core Viewpoint - Suzhou Ribo BioTechnology Co., Ltd. has submitted its A1 listing application to the Hong Kong Stock Exchange, marking a significant step in its development as a pioneer in RNA interference (RNAi) technology and small nucleic acid drug commercialization [1] Group 1: Company Overview - Ribo Bio was established in 2007 and is one of the earliest pioneers in the field of RNAi technology [1] - The company has received strategic investments from several well-known institutions, including Junlian Capital and Guotou Innovation [1] Group 2: Market Potential - The global small nucleic acid drug market has grown from $2.7 billion in 2019 to $4.6 billion in 2023, with a compound annual growth rate (CAGR) of 14.3%, and is expected to reach $46.7 billion by 2033 [2] - siRNA drugs are seen as a disruptive innovation in the pharmaceutical industry, with clinical success rates improving from below 10% for traditional drugs to over 60% for siRNA [2] Group 3: Product Pipeline - Ribo Bio currently has six self-developed siRNA drugs in clinical trials, with four in Phase II trials and over 20 preclinical assets in development [4] - The key product RBD4059 is the first siRNA drug for thrombotic diseases and is progressing rapidly in clinical trials [6] - RBD5044 targets high triglycerides and is the second siRNA drug targeting APOC3 to enter clinical development [7] - RBD7022 is a promising candidate for treating high cholesterol, showing comparable LDL-C reduction to the approved drug Inclisiran [8] - RBD1016 is a key candidate for chronic hepatitis B treatment, showing good safety and efficacy in early trials [9] Group 4: Technological Advancements - Ribo Bio has developed the RiboGalSTAR™ liver-targeting delivery platform, which has shown strong efficacy and safety in clinical studies [12] - The company has established a comprehensive R&D network with nearly 300 researchers and has a production line compliant with EU GMP standards [11] Group 5: Strategic Collaborations - Ribo Bio has entered a significant collaboration with Boehringer Ingelheim, valued at over $2 billion, marking a notable recognition of its RNAi technology platform [13] - The company aims to leverage its innovative capabilities and global partnerships to enhance its position in the small nucleic acid drug market [13]